Ultevursen for Vision Impairments
Trial Summary
What is the purpose of this trial?
This trial tests a drug called ultevursen, which is injected into the eye, for patients with a specific genetic form of Retinitis Pigmentosa. The drug targets and modifies the genetic mutation causing their vision loss.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, if you are on treatments that affect the immune system or have used investigational drugs recently, you may need to discuss this with the trial team.
What data supports the effectiveness of the treatment Ultevursen for Retinitis Pigmentosa?
Research Team
Sepul Bio Medical Monitor
Principal Investigator
Sepul Bio
Sepul Bio Clinical Operations Director
Principal Investigator
Sepul Bio
Eligibility Criteria
This trial is for adults and minors with parental consent who have Retinitis Pigmentosa due to USH2A gene mutations. Participants must have a certain level of vision in both eyes, no treatment history with genetic or stem-cell therapy, and not be allergic to the study medication components.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a loading dose of ultevursen on Day 1, followed by maintenance doses at Month 3 and every 6 months thereafter
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ultevursen
Ultevursen is already approved in European Union, United States for the following indications:
- Orphan designation for Usher syndromes
- Currently in Phase 2b clinical trial for Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laboratoires Thea
Lead Sponsor
ProQR Therapeutics
Lead Sponsor
Sepul Bio
Collaborator
Sepul Bio
Industry Sponsor